ALGS Q1 2021 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$910,000

Gross Profit

$910,000100.0% margin

Operating Income

-$28M-3048.4% margin

Net Income

-$28M-3041.1% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$235M

Total Liabilities

$39M

Stockholders' Equity

$195M

Cash & Equivalents

$200M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$910,000	$0	—
Gross Profit	$910,000	$0	—
Operating Income	-$28M	-$21M	-33.9%
Net Income	-$28M	-$20M	-38.2%